|Bid||34.13 x 1600|
|Ask||34.14 x 500|
|Day's Range||33.87 - 34.21|
|52 Week Range||25.55 - 35.60|
|PE Ratio (TTM)||25.52|
|Dividend & Yield||1.90 (5.50%)|
|1y Target Est||N/A|
The pharma and biotech industry has been blessed with good health in the first half of the year.
Zacks Industry Outlook Highlights: Johnson & Johnson, Incyte, Pfizer, Novartis and AstraZeneca
AstraZeneca PLC (AZN) announced that the CHMP of the European Medicines Agency has adopted a positive opinion recommending the marketing authorisation of Faslodex for 1st-line treatment for postmenopausal women with HR+ advanced breast cancer.